Literature DB >> 18979165

Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice.

Hiroaki Nakamura1, Toru Hiraga, Tadashi Ninomiya, Akihiro Hosoya, Noboru Fujisaki, Toshiyuki Yoneda, Hidehiro Ozawa.   

Abstract

To clarify the mechanisms of bone destruction associated with bone metastases, we studied an animal model in which inoculation of MDA-MB-231 human breast cancer cells into the left cardiac ventricle of female nude mice causes osteolytic lesions in bone using morphological techniques. On the bone surfaces facing the metastatic tumor cells, there existed many tartrate-resistant acid phosphatase (TRAP)-positive multinucleated osteoclasts. TRAP-positive mononuclear osteoclast precursor cells were also observed in the tumor nests. Immunohistochemical studies showed that the cancer cells produced parathyroid hormone-related protein (PTHrP) but not receptor activator of NF-kappaB ligand (RANKL). Histochemical and immunohistochemical examinations demonstrated that alkaline phosphatase and RANKL-positive stromal cells were frequently adjacent to TRAP-positive osteoclast-like cells. Immunoelectron microscopic observation revealed that osteoclast-like cells were in contact with RANKL-positive stromal cells. MDA-MB-231 cells and osteoclast-like cells in the tumor nests showed CD44-positive reactivity on their plasma membranes. Hyaluronan (HA) and osteopontin (OPN), the ligands for CD44, were occasionally colocalized with CD44. These results suggest that tumor-producing osteoclastogenic factors, including PTHrP, upregulate RANKL expression in bone marrow stromal cells, which in turn stimulates the differentiation and activation of osteoclasts, leading to the progression of bone destruction in the bone metastases of MDA-MB-231 cells. Because the interactions between CD44 and its ligands, HA and OPN, have been shown to upregulate osteoclast differentiation and function, in addition to the cell-cell interactions mediated by RANK and RANKL, the cell-matrix interactions mediated by these molecules may also contribute to the progression of osteoclastic bone destruction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18979165     DOI: 10.1007/s00774-008-0857-1

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  30 in total

Review 1.  Signaling properties of hyaluronan receptors.

Authors:  Eva A Turley; Paul W Noble; Lilly Y W Bourguignon
Journal:  J Biol Chem       Date:  2001-11-20       Impact factor: 5.157

Review 2.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

3.  Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44.

Authors:  Jay J Cao; Patrick A Singleton; Sharmila Majumdar; Benjamin Boudignon; Andrew Burghardt; Pam Kurimoto; Thomas J Wronski; Lilly Y W Bourguignon; Bernard P Halloran
Journal:  J Bone Miner Res       Date:  2004-10-18       Impact factor: 6.741

4.  Scanning electron microscopy in bone pathology: review of methods, potential and applications.

Authors:  A Boyde; E Maconnachie; S A Reid; G Delling; G R Mundy
Journal:  Scan Electron Microsc       Date:  1986

5.  Breast cancer cells interact with osteoblasts to support osteoclast formation.

Authors:  R J Thomas; T A Guise; J J Yin; J Elliott; N J Horwood; T J Martin; M T Gillespie
Journal:  Endocrinology       Date:  1999-10       Impact factor: 4.736

6.  Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer.

Authors:  J Southby; M W Kissin; J A Danks; J A Hayman; J M Moseley; M A Henderson; R C Bennett; T J Martin
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

7.  Localization of CD44 (hyaluronan receptor) and hyaluronan in rat mandibular condyle.

Authors:  Hiroaki Nakamura; Ryoko Kato; Azumi Hirata; Miho Inoue; Toshio Yamamoto
Journal:  J Histochem Cytochem       Date:  2005-01       Impact factor: 2.479

8.  Ultrastructural and cytobiological studies on possible interactions between PTHrP-secreting tumor cells, stromal cells, and bone cells.

Authors:  Masahiro Ito; Norio Amizuka; Shohei Tanaka; Yukiko Funatsu-Ozawa; Shin-ichi Kenmotsu; Kimimitsu Oda; Tamio Nakajima; Hidehiro Ozawa
Journal:  J Bone Miner Metab       Date:  2003       Impact factor: 2.626

9.  Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro.

Authors:  S R Rittling; H N Matsumoto; M D McKee; A Nanci; X R An; K E Novick; A J Kowalski; M Noda; D T Denhardt
Journal:  J Bone Miner Res       Date:  1998-07       Impact factor: 6.741

10.  Hyaluronan-CD44 interaction hampers migration of osteoclast-like cells by down-regulating MMP-9.

Authors:  Paola Spessotto; Francesca Maria Rossi; Massimo Degan; Raffaele Di Francia; Roberto Perris; Alfonso Colombatti; Valter Gattei
Journal:  J Cell Biol       Date:  2002-09-16       Impact factor: 10.539

View more
  10 in total

1.  Fish oil prevents breast cancer cell metastasis to bone.

Authors:  Chandi Charan Mandal; Triparna Ghosh-Choudhury; Toshi Yoneda; Goutam Ghosh Choudhury; Nandini Ghosh-Choudhury
Journal:  Biochem Biophys Res Commun       Date:  2010-10-28       Impact factor: 3.575

2.  Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44.

Authors:  Chandi Charan Mandal; Nayana Ghosh-Choudhury; Toshi Yoneda; Goutam Ghosh Choudhury; Nandini Ghosh-Choudhury
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

3.  Inhibitory effect of cathepsin K inhibitor (ODN-MK-0822) on invasion, migration and adhesion of human breast cancer cells in vitro.

Authors:  Yaongamphi Vashum; Riya Premsingh; Amuthavalli Kottaiswamy; Mathangi Soma; Abirami Padmanaban; Parkavi Kalaiselvan; Shila Samuel
Journal:  Mol Biol Rep       Date:  2020-12-08       Impact factor: 2.316

4.  Integrin α(v)β₃ as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation.

Authors:  Alexander Zheleznyak; Thaddeus J Wadas; Christopher D Sherman; Jessica M Wilson; Paul J Kostenuik; Katherine N Weilbaecher; Carolyn J Anderson
Journal:  Mol Imaging Biol       Date:  2012-08       Impact factor: 3.488

5.  The reaction of bone to tumor growth from human breast cancer cells in a rat spine single metastasis model.

Authors:  Haixiang Liang; Shen-Ying Ma; Khalid Mohammad; Theresa A Guise; Gary Balian; Francis H Shen
Journal:  Spine (Phila Pa 1976)       Date:  2011-04-01       Impact factor: 3.468

6.  PTHrP inhibits BMP-6 expression through the PKA signaling pathway in breast cancer cells.

Authors:  Dong Mi; Ming Zhang; Ji-dong Yan; Jie Zhang; Xu Wang; Qing Wang; Shuang Yang; Tian-hui Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-18       Impact factor: 4.553

7.  US-guided interstitial chemotherapy using paclitaxel temperature-responsive gel for breast cancer treatment in rat.

Authors:  Zhi-kui Chen; Li-wu Lin; Ying-hong Yang; Hua-jing Cai; Jia-jia Yang; Min-xian Cai
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-24       Impact factor: 4.553

8.  DHA is a more potent inhibitor of breast cancer metastasis to bone and related osteolysis than EPA.

Authors:  Md Mizanur Rahman; Jyothi Maria Veigas; Paul J Williams; Gabriel Fernandes
Journal:  Breast Cancer Res Treat       Date:  2013-09-24       Impact factor: 4.872

Review 9.  Targeting RANKL in metastasis.

Authors:  William C Dougall; Ingunn Holen; Eva González Suárez
Journal:  Bonekey Rep       Date:  2014-04-09

10.  BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.

Authors:  Elisabet Cuyàs; Bruna Corominas-Faja; María Muñoz-San Martín; Begoña Martin-Castillo; Ruth Lupu; Joan Brunet; Joaquim Bosch-Barrera; Javier A Menendez
Journal:  Oncotarget       Date:  2017-05-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.